Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Worldwide Point-of-Care (POC) Diagnostic Tests Market Research 2024: Focus on Prevention and Early Detection Drives Development of POC Solutions - ResearchAndMarkets.com


The "The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024" report has been added to ResearchAndMarkets.com's offering.

The geographic scope of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 is global, with information for specific geographical regions, world demographics, and other general issues affecting the market. The report's market summary includes total market values, market analysis by product, test usage, technology, region, end-use and a competitive analysis of leading providers. Additionally, key company profiles are included.

Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in vitro diagnostics (IVD) industry. However, the point-of-care (POC) segment is seen as a key growth area. Point-of-care refers to tests that can provide meaningful results during a provider visit or in the patient's home.

Over the past two decades, the publisher has observed that POC tests present significant opportunities for expansion. This rich history analyzing the market is at the forefront of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024, the eleventh edition in the publisher's POC report series.

The role of diagnostics in promoting wellness, improving patient-provider encounters, aiding in drug selection and stewardship, facilitating home or nursing home care, and ensuring effective pandemic management relies heavily on the success of point-of-care solutions. The global POC testing market has experienced significant growth in the last two decades due to the increasing demand for accurate and rapid testing, both within and outside hospital settings. Technological advancements in smartphones, biosensors, lab-on-a-chip, and wearable devices have influenced the POC landscape, aiming to provide expedited diagnosis at the point-of-care.

As a result, point-of-care diagnostics can command higher pricing and experience larger revenue growth compared to lab-based tests. The tests covered in The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 tend to grow at higher rates than the overall IVD market.

Venue Market Analysis

POC tests are conducted in various settings, including hospital departments (emergency, operating rooms, intensive care units), physicians' offices, hospital clinics, retail clinics, pharmacies, homes (self-testing or by caregivers), and nursing homes.

POC testing may be performed by laboratory personnel, but often it is performed by non-laboratory personnel such as physicians, nurses, assistants in medical offices, emergency medical technicians (EMTs), medics, pharmacists, and the patients themselves (self-testing). Some POC tests are manual tests, often performed with technologies based on dipsticks or strips, lateral flow cassettes, or other manual tests. There are also many small, portable instruments that have been developed for use in POC settings. With the advances in miniaturization and microfluidics that have occurred in recent years, a growing number of small, handheld devices are reaching the POC market for a range of different testing applications.

Corporate Profiles

The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 also highlights the contribution of POC test devices to the overall diagnostics market growth. More diagnostic manufacturers are seeking CLIA waiver status or CE Mark for their POC devices, indicating the growing importance of POC testing in diagnosis and patient care monitoring. Rapid tests are also becoming more prevalent in the POC arena, allowing physicians to treat patients more effectively and efficiently.

Scope and Methodology

All market data pertains to the world market at the manufacturers' level. The market includes manufacturer tests excluding services. The base year for data was 2023. Forecast data is provided for 2023 through 2028. Compound annual growth rates (CAGRs) are provided for the 2023-2028 period for each segment covered. Competitive analysis is provided for the year 2023 along with regional breakdowns. The forecasted market analysis for 2023-2028 was largely based on demographic trends, new developments, innovative technology and global expansion.

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Introduction and Overview

Chapter 3: POC Blood Glucose Tests

Chapter 4: POC Blood and Electrolytes Testing Market

Chapter 5: POC Rapid Coagulation

Chapter 6: POC Rapid Cardiac Markers

Chapter 7: POC Substance Abuse

Chapter 8: POC Pregnancy and Fertility Testing

Chapter 9: POC Colon Cancer Screening/Fecal Occult Blood Testing

Chapter 10: POC Infectious Disease Testing

Chapter 11: POC Lipid Testing

Chapter 12: POC Cancer Tumor Marker Testing

Chapter 13: POC Urine Testing

Chapter 14: Miscellaneous POC Testing

Chapter 15: Issues and Trends

Chapter 16: Total Global POC Testing Market and Competitor Analysis

Chapter 17: Corporate Profiles

For more information about this report visit https://www.researchandmarkets.com/r/uo3da1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: